Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis (ESCAPE-NEXT)

The primary purpose of this study is to determine if a single dose of nerinetide can reduce neurological disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen activator (alteplase, tenecteplase, or equivalent). A randomized treatment study comparing the efficacy of an investigational neuroprotectant infusion (nerinetide) in stroke patients ineligible for thrombolysis who are treated with emergency thrombectomy.

Check your eligibility (clinicaltrials.gov)
Participate in a Clinical Trial at Saint John’s Cancer Institute.

Questions regarding this trial: 310-303-5515